Aarkstore - Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2014 - PowerPoint PPT Presentation

About This Presentation
Title:

Aarkstore - Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2014

Description:

This report provides comprehensive information on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Browse full report @ – PowerPoint PPT presentation

Number of Views:70

less

Transcript and Presenter's Notes

Title: Aarkstore - Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2014


1
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline
Review, H2 2014
Pharmaceutical and Healthcare Market Research
Report
2
Summary
  • Vaginal Atrophy (Atrophic Vaginitis) - Pipeline
    Review, H2 2014, provides an overview of the
    Vaginal Atrophy (Atrophic Vaginitis)s therapeutic
    pipeline.
  • This report provides comprehensive information
    on the therapeutic development for Vaginal
    Atrophy (Atrophic Vaginitis), complete with
    comparative analysis at various stages,
    therapeutics assessment by drug target, mechanism
    of action (MoA), route of administration (RoA)
    and molecule type, along with latest updates, and
    featured news and press releases. It also reviews
    key players involved in the therapeutic
    development for Vaginal Atrophy (Atrophic
    Vaginitis) and special features on late-stage and
    discontinued projects.
  • Global Markets Directs report features
    investigational drugs from across globe covering
    over 20 therapy areas and nearly 3,000
    indications. The report is built using data and
    information sourced from Global Markets Directs
    proprietary databases, Company/University
    websites, SEC filings, investor presentations and
    featured press releases from company/university
    sites and industry-specific third party sources,
    put together by Global Markets Directs team.

3
Scope
  • - The report provides a snapshot of the global
    therapeutic landscape of Vaginal Atrophy
    (Atrophic Vaginitis)- The report reviews key
    pipeline products under drug profile section
    which includes, product description, MoA and RD
    brief, licensing and collaboration details
    other developmental activities - The report
    reviews key players involved in the therapeutics
    development for Vaginal Atrophy (Atrophic
    Vaginitis) and enlists all their major and minor
    projects- The report summarizes all the dormant
    and discontinued pipeline projects - A review of
    the Vaginal Atrophy (Atrophic Vaginitis) products
    under development by companies and
    universities/research institutes based on
    information derived from company and
    industry-specific sources- Pipeline products
    coverage based on various stages of development
    ranging from pre-registration till discovery and
    undisclosed stages
  • Browse full report or Sample Request _at_
  • http//www.aarkstore.com/pharmaceuticals-healthcar
    e/100597/vaginal-atrophy-atrophic-vaginitis-pipeli
    ne-review-h2-2014

4
Reasons to buy
  • - Provides strategically significant competitor
    information, analysis, and insights to formulate
    effective RD development strategies- Identify
    emerging players with potentially strong product
    portfolio and create effective counter-strategies
    to gain competitive advantage- Develop strategic
    initiatives by understanding the focus areas of
    leading companies- Identify and understand
    important and diverse types of therapeutics under
    development for Vaginal Atrophy (Atrophic
    Vaginitis)- Plan mergers and acquisitions
    effectively by identifying key players of the
    most promising pipeline- Devise corrective
    measures for pipeline projects by understanding
    Vaginal Atrophy (Atrophic Vaginitis) pipeline
    depth and focus of Indication therapeutics-
    Develop and design in-licensing and out-licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and Scope- Modify the
    therapeutic portfolio by identifying discontinued
    projects and understanding the factors that drove
    them from pipeline

5
Table of Content
  • IntroductionREPORT COVERAGEVaginal Atrophy
    (Atrophic Vaginitis) OverviewTherapeutics
    DevelopmentPipeline Products for Vaginal Atrophy
    (Atrophic Vaginitis) - OverviewPipeline Products
    for Vaginal Atrophy (Atrophic Vaginitis) -
    Comparative AnalysisVaginal Atrophy (Atrophic
    Vaginitis) - Therapeutics under Development by
    CompaniesVaginal Atrophy (Atrophic Vaginitis) -
    Pipeline Products GlanceLate Stage
    ProductsClinical Stage ProductsEarly Stage
    ProductsVaginal Atrophy (Atrophic Vaginitis) -
    Products under Development by CompaniesVaginal
    Atrophy (Atrophic Vaginitis) - Companies Involved
    in Therapeutics DevelopmentFoamix Ltd.Pantarhei
    Bioscience BV

6
List of Tables
  • Number of Products under Development for Vaginal
    Atrophy (Atrophic Vaginitis), H2 2014Number of
    Products under Development for Vaginal Atrophy
    (Atrophic Vaginitis) - Comparative Analysis, H2
    2014Number of Products under Development by
    Companies, H2 2014Comparative Analysis by Late
    Stage Development, H2 2014Comparative Analysis
    by Clinical Stage Development, H2
    2014Comparative Analysis by Early Stage
    Development, H2 2014Products under Development
    by Companies, H2 2014Vaginal Atrophy (Atrophic
    Vaginitis) - Pipeline by Foamix Ltd., H2
    2014Vaginal Atrophy (Atrophic Vaginitis) -
    Pipeline by Pantarhei Bioscience BV, H2
    2014Vaginal Atrophy (Atrophic Vaginitis) -
    Pipeline by Hygeia Therapeutics, Inc., H2
    2014Vaginal Atrophy (Atrophic Vaginitis) -
    Pipeline by EndoCeutics, Inc., H2 2014Vaginal
    Atrophy (Atrophic Vaginitis) - Pipeline by
    TherapeuticsMD Inc., H2 2014Vaginal Atrophy
    (Atrophic Vaginitis) - Pipeline by Peptonic
    medical AB, H2 2014

7
List of Figures
  • Number of Products under Development for Vaginal
    Atrophy (Atrophic Vaginitis), H2 2014Number of
    Products under Development for Vaginal Atrophy
    (Atrophic Vaginitis) - Comparative Analysis, H2
    2014Number of Products under Development by
    Companies, H2 2014Assessment by Monotherapy
    Products, H2 2014Number of Products by Top 10
    Target, H2 2014Number of Products by Stage and
    Top 10 Target, H2 2014Number of Products by Top
    10 Mechanism of Action, H2 2014Number of
    Products by Stage and Top 10 Mechanism of Action,
    H2 2014Number of Products by Top 10 Route of
    Administration, H2 2014Number of Products by
    Stage and Top 10 Route of Administration, H2
    2014Number of Products by Top 10 Molecule Type,
    H2 2014Number of Products by Stage and Top 10
    Molecule Type, H2 2014

8
Related Reports
  • Sinusitis-Pipeline Insights, 2015
  • Oligodendroglioma-Pipeline Insights, 2015
  • Familial Hypercholesterolemia (Type II
    Hyperlipoproteinemia)-Pipeline Insights, 2015
  • Fatty Liver Disease-Pipeline Insights, 2015
  • Skin And Skin Structure Infections by
    S.Pneumoniae-Pipeline Insights, 2015
  • Opioid-Induced Constipation (OIC)-Pipeline
    Insights, 2015
  • Female Infertility-Pipeline Insights, 2015
  • Optic Neuritis-Pipeline Insights, 2015

9
Follow Us
https//www.facebook.com/aarkstoredotcom
https//twitter.com/aarkstore
https//plus.google.com/Aarkstoredotcom/posts
https//www.linkedin.com/company/aarkstore-enterpr
ise
10
Contact Us
Office Address Office No. - 809, 8th
Floor,B-Wing, Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Mail us at
contact_at_aarkstore.com 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
Write a Comment
User Comments (0)
About PowerShow.com